Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- WORLD NEWS IN BRIEF
October 27, 2003
- WEBSITE NEWS
October 27, 2003
- Taiyo Expects Strong Growth in Contract Manufacturing Business
October 27, 2003
- Semiannual Business Results
October 27, 2003
- Kyorin Is Pursuing 4 Scenarios for Independent Marketing in US
October 27, 2003
- Fujisawa, Yamanouchi to Merge OTC Drug Businesses
October 27, 2003
- BULLETIN
October 27, 2003
- Taisho to Be Exclusive Sales Agent for P&G's Vicks VapoRub
October 27, 2003
- Wholesalers' FY2003 Results Could Be Worse than FY2001's: Mr Kimura
October 27, 2003
- WG to Select OTC Drugs "With No Particular Problems in Regard to Safety"
October 27, 2003
- More Pharma Companies Outsourcing Call Center Work: Bell System 24
October 27, 2003
- Inauguration of Insurance Pharmacy Association Expected Next Spring
October 27, 2003
- Domain Associates Announce Novel Licensing Agreements with Takeda, Kyowa Hakko
October 27, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 27, 2003
- BUSINESS NEWS IN BRIEF
October 27, 2003
- MEDICAL DEVICE NEWS IN BRIEF
October 27, 2003
- BULLETIN
October 27, 2003
- DIAGNOSTIC NEWS IN BRIEF
October 27, 2003
- WEBSITE NEWS
October 27, 2003
- Most GE Houses Forecast Growth in FY2003: EPMA Survey
October 27, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…